ClinicalTrials.gg
CompletedNCT07937059Updated Nov 13, 2026

Observational Study With Erosive Gastroesophageal Reflux Disease With JAQBO® ODT

An observational study in Erosive Gastroesophageal Reflux Disease, sponsored by Jeil Pharmaceutical Co., Ltd.. Completed at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Jeil Pharmaceutical Co., Ltd. · Observational

Updated Nov 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,183
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of — 8 open to participants now, 10 under way, none of them phase 3. Gastroesophageal Reflux · Korea, Republic of.

Enrollment
7th of 19
5,183 · median 2,000
Started
2026
with 1 other
Observational
19 of 71
3 open now
Registered
71st of 71
by date
Lead sponsor
3 of 71
Jeil Pharmaceutical Co., Ltd.

Among the 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of, this one is the 7th largest by enrollment of the 19 observational ones that give a count, is one of 2 that started in 2026, is one of 19 observational ones, and was the 71st registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

8 of the 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate patient characteristics, effectiveness, safety, and satisfaction in patients treated with JAQBO® ODT. 20 mg(Zastaprazan citrate) for Erosive Gastroesophageal Reflux Disease in a real-world clinical setting.

03

Conditions studied

  • Erosive Gastroesophageal Reflux Disease
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with Erosive Gastroesophageal Reflux Disease who are scheduled to receive or are treated with JAQBO® ODT 20 mg (zastaprazan citrate) in routine clinical practice

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects aged 19 years or older
  • Subjects who, at the investigator's discretion, are scheduled to receive JAQBO® ODT 20mg (Zastaprazan Citrate) for the treatment of Erosive Gastroesophageal Reflux Disease
  • Subjects who have voluntarily decided to participate in this observational study and have provided written after receiving the study information and consent form

Exclusion criteria

Exclusion Criteria:

  • Pregnant or Lactating Women
  • Subjects with to JAQBO® ODT 20 mg (zastaprazan citrate) according to the approved prescribing information
  • Subjects deemed inappropriate for participation in the study at the investigator's discretion.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,183 participants (actual)
Patient registry
No

Groups and cohorts

  • JAQBO® ODT 20 mg-Treated Patients
06

What researchers measure

Primary outcomes

  1. Change in Reflux Disease Questionnaire (RDQ) at Week 4

    This questionnaire is a self-reported instrument designed to assess the main symptoms of gastroesophageal reflux disease (GERD), including heartburn, acid regurgitation, and dyspepsia. It consists of a total of 12 items, each evaluating the frequency and severity of symptoms using a 6-point scale (0 to 5). In this observational study, only heartburn and acid regurgitation symptoms are assessed. The questionnaire is completed by the study participants themselves, and higher total scores indicate more severe symptoms.

    Time frame: baseline/4week

07

Study locations

1 site
  • Seoul happiness clinic of internal medicine
    Seongnam-si, Gyeonggi-do 13612, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2026 to primary completion in Jul 2026, 4 months.

Of 117 observational studies under Gastroesophageal Reflux, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 134. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2026
First posted
Nov 13, 2026
StartActual
Feb 26, 2026
Primary completionActual
Jul 9, 2026
CompletionActual
Jul 9, 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07937059
Responsible party
Sponsor
First posted
Nov 13, 2026
Start date
Feb 26, 2026
Primary completion
Jul 9, 2026
Completion
Jul 9, 2026
Last update
Nov 13, 2026

Study contacts

Changhyun Lee
principal investigator · Seoul happiness clinic of internal medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion